Nusinersen
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Using no additional skill — this is a direct report-writing task per the given template; proceeding directly.
Nusinersen: From Spinal Muscular Atrophy to Skin Atrophy
One-Sentence Summary
Nusinersen is an antisense oligonucleotide administered intrathecally to restore SMN protein production in Spinal Muscular Atrophy (SMA). The TxGNN model flags a possible link to Skin Atrophy, but the 3 clinical trials and 6 publications returned as “evidence” are not actually studies of nusinersen for skin atrophy — they concern SMA lumbar-puncture technique and incidental injection-site skin necrosis, meaning this candidate is currently unsupported.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Spinal Muscular Atrophy (SMA) — per embedded trial descriptions (“first treatment approved by FDA and EMA for all SMA subtypes”); not present in this market’s regulatory data |
| Predicted New Indication | Skin atrophy |
| TxGNN Prediction Score | 50% (raw score 0.5; global rank 1,181,204 — very low priority among all predictions) |
| Evidence Level | L4 |
| Market Status | ✗ Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for nusinersen is not available in the structured original_moa field (Data Gap). However, the evidence pack’s own analysis identifies nusinersen as an antisense oligonucleotide that targets SMN2 pre-mRNA splicing, given intrathecally to increase functional SMN protein for the treatment of SMA — a neuromuscular, not dermatologic, mechanism.
There is no established or plausible mechanistic link between SMN2 splicing modulation and skin atrophy. Skin atrophy is typically driven by dermal collagen/elastin loss (e.g., corticosteroid use, aging, connective tissue disease) — pathways unrelated to motor neuron RNA splicing.
The apparent “evidence” behind this prediction is a keyword-co-occurrence artifact: retrieved trials and literature describe SMA patients receiving nusinersen via lumbar puncture (some with scoliosis or spinal instrumentation), and one case report describes resolution of localized injection-site skin necrosis — not therapeutic use of nusinersen for a skin-atrophy indication. The evidence pack’s own relevance grading (Grade C) and rationale text explicitly flag this as a likely false-positive pairing rather than a genuine repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04674618 | N/A | Completed | 58 | Compares ultrasound-assisted vs. landmark-based intrathecal nusinersen administration in adult SMA patients; addresses injection technique, not skin atrophy (relevance: Grade C) |
| NCT05644899 | N/A | Completed | 51 | Retrospective analysis of >500 intrathecal nusinersen administrations in SMA adults with scoliosis; procedural study, not a skin-atrophy trial (relevance: Grade C) |
| NCT06555419 | Phase 1 | Recruiting | 58 | Pharmacokinetic study of nusinersen delivered via the ThecaFlex DRx™ implantable system vs. lumbar puncture in SMA patients; not related to skin atrophy (relevance: Grade C) |
Note: None of the above trials evaluate nusinersen as a treatment for skin atrophy; all concern intrathecal delivery technique in SMA.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40241365 | 2025 | Case series | Zhongguo Dang Dai Er Ke Za Zhi | Nusinersen + risdiplam combination therapy in 10 SMA patients; efficacy/adverse reactions, not skin atrophy |
| 39010073 | 2024 | Technique report | Orphanet J Rare Dis | Novel interlaminar approach for intrathecal nusinersen injection in SMA patients with scoliosis |
| 30811610 | 2019 | Case report | Muscle & Nerve | Resolution of localized skin necrosis at injection site in an infant treated with nusinersen — an adverse event report, not a treatment-efficacy finding for skin atrophy |
| 32515646 | 2020 | Case report | J Child Neurol | SMA Type 0 patient treated with nusinersen and onasemnogene abeparvovec; motor outcome case report |
| 37155209 | 2023 | Case series/technique | Minerva Pediatrics | Surgical technique enabling intrathecal nusinersen injection after spinal fusion in SMA patients |
| 39344612 | 2024 | Case report | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | Genetic/functional analysis of SMN1 variants in two SMA children |
Note: All retrieved literature concerns SMA management or intrathecal-injection technique/complications; none evaluates nusinersen as a treatment for skin atrophy.
Market Information
No marketing authorizations are on file for this market — nusinersen’s status here is “Not marketed” (Not marketed), with 0 recorded licenses. No approved indication text is available from this dataset.
Safety Considerations
Please refer to the SmPC for safety information (product labeling, warnings, and drug-interaction data were not available in this evidence pack).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score (0.5) corresponds to an extremely low global rank (~1.18 million), and every supporting clinical trial and publication is unrelated to skin atrophy — they concern SMA injection technique or incidental injection-site skin necrosis. There is no mechanistic or clinical rationale connecting SMN2 splicing modulation to skin atrophy; this candidate is best characterized as a keyword-co-occurrence false positive rather than a genuine repurposing signal.
To proceed, the following is needed:
- Independent, disease-specific mechanistic rationale linking nusinersen to a dermatologic atrophic process (none currently exists)
- Nusinersen product label / MOA data (currently a Blocking data gap per DG001/DG002) before any safety evaluation can begin
- Any genuine preclinical or clinical study directly testing nusinersen in skin atrophy — none currently exists in this evidence pack
- Given the absence of supporting rationale, deprioritize this candidate in favor of other predicted indications with stronger mechanistic plausibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.